Fujian Cosunter Pharmaceutical Co Ltd Market Cap ($1.80 Billion)
Market Cap & Net Worth: Fujian Cosunter Pharmaceutical Co Ltd (300436)
Fujian Cosunter Pharmaceutical Co Ltd market cap. Fujian Cosunter Pharmaceutical Co Ltd (SHE:300436) has a market capitalization of $1.80 Billion (CN¥12.27 Billion) as of October 31, 2026. Listed on the SHE stock exchange, this China-based company holds position #6328 globally and #1186 in its home market, demonstrating a -8.57% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Fujian Cosunter Pharmaceutical Co Ltd's stock price CN¥73.05 by its total outstanding shares 168026389 (168.03 Million).
Fujian Cosunter Pharmaceutical Co Ltd Market Cap History (2015–2026)
Fujian Cosunter Pharmaceutical Co Ltd market cap history from 2015 to 2026. Data shows growth from $2.02 Billion to $1.80 Billion (0.42% CAGR). Check current stock price of Fujian Cosunter Pharmaceutical Co Ltd for real-time trading data and today's change.
Fujian Cosunter Pharmaceutical Co Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Fujian Cosunter Pharmaceutical Co Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Also see 300436 cash flow metrics for how efficiently the company converts equity into cash flow.
Latest Price to Sales (P/S) Ratio
5.26x
Fujian Cosunter Pharmaceutical Co Ltd's market cap is 5.26 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $1.32 Billion | $312.88 Million | $66.41 Million | 4.21x | 19.83x |
| 2017 | $720.08 Million | $296.12 Million | $33.57 Million | 2.43x | 21.45x |
| 2018 | $596.25 Million | $402.40 Million | $16.48 Million | 1.48x | 36.17x |
| 2019 | $819.01 Million | $414.87 Million | $10.74 Million | 1.97x | 76.24x |
| 2020 | $950.06 Million | $368.49 Million | $14.82 Million | 2.58x | 64.09x |
| 2021 | $1.18 Billion | $370.44 Million | -$34.89 Million | 3.19x | N/A |
| 2022 | $962.85 Million | $385.77 Million | -$127.40 Million | 2.50x | N/A |
| 2023 | $630.18 Million | $422.71 Million | -$348.59 Million | 1.49x | N/A |
| 2024 | $803.28 Million | $441.46 Million | -$156.30 Million | 1.82x | N/A |
| 2025 | $2.19 Billion | $416.37 Million | -$217.85 Million | 5.26x | N/A |
Competitor Companies of 300436 by Market Capitalization
Companies near Fujian Cosunter Pharmaceutical Co Ltd in the global market cap rankings as of October 31, 2026. See Fujian Cosunter Pharmaceutical Co Ltd (300436) balance sheet quality index to understand what proportion of total assets are financed by equity.
Key companies related to Fujian Cosunter Pharmaceutical Co Ltd by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #515 globally with a market cap of $52.60 Billion USD.
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #536 globally with a market cap of $50.42 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #600 globally with a market cap of $45.38 Billion USD ( CN¥310.15 Billion CNY).
- Takeda Pharmaceutical Company Limited (F:TKDA): Ranked #626 globally with a market cap of $43.60 Billion USD ( €37.29 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #515 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #536 | GALDERMA GROUP AG | NYSE:GALDY | $50.42 Billion | $45.98 |
| #600 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $45.38 Billion | CN¥48.62 |
| #626 | Takeda Pharmaceutical Company Limited | F:TKDA | $43.60 Billion | €17.90 |
Market Capitalization of Fujian Cosunter Pharmaceutical Co Ltd (2015–2026)
Market capitalization of Fujian Cosunter Pharmaceutical Co Ltd from 2015 to today. Between 2015 and today, Fujian Cosunter Pharmaceutical Co Ltd's market cap moved from $2.02 Billion to $ 1.80 Billion, with a yearly change of 0.42%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CN¥1.80 Billion | -18.06% |
| 2025 | CN¥2.19 Billion | +172.88% |
| 2024 | CN¥803.28 Million | +27.47% |
| 2023 | CN¥630.18 Million | -34.55% |
| 2022 | CN¥962.85 Million | -18.47% |
| 2021 | CN¥1.18 Billion | +24.30% |
| 2020 | CN¥950.06 Million | +16.00% |
| 2019 | CN¥819.01 Million | +37.36% |
| 2018 | CN¥596.25 Million | -17.20% |
| 2017 | CN¥720.08 Million | -45.32% |
| 2016 | CN¥1.32 Billion | -34.94% |
| 2015 | CN¥2.02 Billion | -- |
End of Day Market Cap According to Different Sources
On Oct 30th, 2026 the market cap of Fujian Cosunter Pharmaceutical Co Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $1.80 Billion USD |
| MoneyControl | $1.80 Billion USD |
| MarketWatch | $1.80 Billion USD |
| marketcap.company | $1.80 Billion USD |
| Reuters | $1.80 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Fujian Cosunter Pharmaceutical Co Ltd
Fujian Cosunter Pharmaceutical Co., Ltd. engages in the research and development, manufacture, and sale of pharmaceutical products in China. The company offers drugs for anti-HBV, liver diseases, hepatobiliary disease drugs, metabolism and digestive system, respiratory, cardiovascular, men's health, and other fields. It also provides technical services such as drug development, including the deve… Read more